BioCell
Irvine, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $110M
Overview
A regenerative medicine company providing amniotic membrane-based allografts for advanced wound care and soft tissue repair.
Regenerative Medicine
Technology Platform
A proprietary processing and preservation platform for human amniotic membrane and fluid, creating allografts that retain native regenerative components for wound and tissue repair.
Funding History
1Total raised:$110M
IPO$110M
Opportunities
Growing demand for advanced biologic wound care solutions in an aging population with increasing rates of diabetes and chronic wounds.
Risk Factors
Market and reimbursement risks, including pricing pressure and scrutiny from payers over the clinical utility and cost-effectiveness of amniotic tissue products.
Competitive Landscape
Competes with several established players in the amniotic tissue and regenerative biologics market on the basis of product format, processing method, clinical data, and price.